Stock News

General American Investors Company Has Lifted Its Paratek Pharmaceuticals (PRTK) Holding; Cushing Asset Management LP Has Boosted Genesee & Wyo (GWR) Position By $1.67 Million

Cushing Asset Management Lp increased Genesee & Wyo Inc (GWR) stake by 35.22% reported in 2017Q3 SEC filing. Cushing Asset Management Lp acquired 22,583 shares as Genesee & Wyo Inc (GWR)’s stock declined 14.44%. The Cushing Asset Management Lp holds 86,695 shares with $6.42 million value, up from 64,112 last quarter. Genesee & Wyo Inc now has $4.48B valuation. The stock increased 2.06% or $1.45 during the last trading session, reaching $71.86. About 467,238 shares traded or 29.55% up from the average. Genesee & Wyoming Inc. (NYSE:GWR) has risen 13.88% since February 15, 2017 and is uptrending. It has underperformed by 2.82% the S&P500.

General American Investors Company Inc increased Paratek Pharmaceuticals Inc. (PRTK) stake by 13.02% reported in 2017Q3 SEC filing. General American Investors Company Inc acquired 40,000 shares as Paratek Pharmaceuticals Inc. (PRTK)’s stock rose 33.85%. The General American Investors Company Inc holds 347,213 shares with $8.72M value, up from 307,213 last quarter. Paratek Pharmaceuticals Inc. now has $440.03M valuation. The stock increased 4.04% or $0.55 during the last trading session, reaching $14.15. About 556,792 shares traded or 19.94% up from the average. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 62.03% since February 15, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. Robert W. Baird maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) rating on Tuesday, October 24. Robert W. Baird has “Buy” rating and $40.0 target. On Thursday, October 27 the stock rating was reinitiated by Leerink Swann with “Outperform”. Wedbush maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) on Tuesday, April 4 with “Outperform” rating. On Wednesday, November 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Ladenburg Thalmann given on Friday, June 17. The firm earned “Buy” rating on Wednesday, August 23 by Cantor Fitzgerald. On Tuesday, July 18 the stock rating was maintained by Leerink Swann with “Buy”. Zacks upgraded the stock to “Hold” rating in Wednesday, September 2 report. On Monday, July 17 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Gabelli initiated Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) on Thursday, July 23 with “Buy” rating.

General American Investors Company Inc decreased Gilead Sciences Inc. (NASDAQ:GILD) stake by 20,000 shares to 463,600 valued at $37.56 million in 2017Q3. It also reduced Apple Inc. (NASDAQ:AAPL) stake by 10,000 shares and now owns 104,000 shares. Diageo Plc Adr (NYSE:DEO) was reduced too.

Investors sentiment decreased to 1.54 in Q3 2017. Its down 0.35, from 1.89 in 2017Q2. It worsened, as 17 investors sold PRTK shares while 29 reduced holdings. 33 funds opened positions while 38 raised stakes. 20.11 million shares or 4.43% more from 19.26 million shares in 2017Q2 were reported. Granite Point Capital Mgmt LP has 0.14% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 14,537 were reported by Art Advsr Limited Company. 9,109 are owned by Appleton Prtn Ma. Axiom Investors Limited Com De reported 0.03% stake. Lpl Lc invested in 39,450 shares. Numeric Investors Limited has invested 0.04% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). New York-based Broadfin Ltd Liability Corp has invested 1.51% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Highbridge Management Ltd Llc accumulated 210,550 shares. Boston Ptnrs holds 133,682 shares. C Hldg A S has 0.23% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 645,100 shares. 268,001 were accumulated by Davidson Kempner Limited Partnership. Zurcher Kantonalbank (Zurich Cantonalbank) has 677 shares. Raymond James Finance Advsrs reported 11,133 shares or 0% of all its holdings. Empyrean Cap Partners Ltd Partnership reported 0.65% stake. Columbus Circle Investors has invested 0.05% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Investors sentiment increased to 1.07 in Q3 2017. Its up 0.08, from 0.99 in 2017Q2. It is positive, as 27 investors sold GWR shares while 82 reduced holdings. 37 funds opened positions while 80 raised stakes. 58.92 million shares or 1.22% more from 58.21 million shares in 2017Q2 were reported. First Mercantile Tru, a Tennessee-based fund reported 3,845 shares. Tower Bridge Advisors reported 0.04% stake. Guyasuta Inv Advisors Inc holds 15,184 shares. 3,939 are held by Ww Asset Mngmt. M&T State Bank stated it has 0.01% in Genesee & Wyoming Inc. (NYSE:GWR). San Francisco Sentry (Ca) holds 43 shares or 0% of its portfolio. Metropolitan Life Insur Ny has 0.03% invested in Genesee & Wyoming Inc. (NYSE:GWR). Dimensional Fund Advisors LP reported 0.05% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Bbva Compass National Bank holds 0.02% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR) for 5,065 shares. Barclays Pcl holds 0% or 7,901 shares. Great West Life Assurance Can has invested 0.01% in Genesee & Wyoming Inc. (NYSE:GWR). 784,178 were reported by Rare Infrastructure Ltd. Natl Bank Of Montreal Can holds 0.01% or 122,651 shares in its portfolio. Renaissance Lc invested in 51,350 shares or 0% of the stock. Villere St Denis J Limited holds 4.06% or 938,344 shares.

Among 13 analysts covering Genesee & Wyoming Inc. (NYSE:GWR), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Genesee & Wyoming Inc. had 43 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, February 22 by Bank of America. Cowen & Co maintained it with “Outperform” rating and $75 target in Wednesday, May 3 report. On Friday, April 29 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. On Tuesday, August 1 the stock rating was maintained by Stifel Nicolaus with “Hold”. Citigroup maintained it with “Buy” rating and $84 target in Friday, February 9 report. The company was downgraded on Friday, December 4 by Bank of America. The stock of Genesee & Wyoming Inc. (NYSE:GWR) has “Hold” rating given on Tuesday, October 31 by Stifel Nicolaus. Susquehanna maintained the shares of GWR in report on Tuesday, January 16 with “Hold” rating. The rating was maintained by Cowen & Co on Tuesday, October 31 with “Buy”. Citigroup maintained Genesee & Wyoming Inc. (NYSE:GWR) on Friday, April 29 with “Buy” rating.

Since August 14, 2017, it had 0 buys, and 5 insider sales for $1.72 million activity. $926,918 worth of stock was sold by HELLMANN JOHN C on Friday, August 25. $255,250 worth of stock was sold by Walsh Matthew O. on Tuesday, August 29. $168,443 worth of Genesee & Wyoming Inc. (NYSE:GWR) shares were sold by Fergus Allison M. Brown David A also sold $275,086 worth of Genesee & Wyoming Inc. (NYSE:GWR) on Monday, August 28. 5,073 shares valued at $339,079 were sold by Gallagher Timothy J on Monday, August 14. $93,755 worth of Genesee & Wyoming Inc. (NYSE:GWR) was sold by Liucci Christopher F.

Leave a Reply

Your email address will not be published. Required fields are marked *